Does Rallies show 13F holders for MREO?

Yes. Rallies tracks hedge fund and 13F ownership data for MREO, including fund names, share counts, latest tracked quarter, and position changes when available.

Is MREO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MREO. It does not provide personalized investment advice.

MREO (Mereo BioPharma Group plc American Depositary Shares) Stock Analysis - Hedge Fund Holdings

Mereo BioPharma Group plc American Depositary Shares (MREO) is a publicly traded Healthcare sector company. As of May 21, 2026, MREO trades at $0.28 with a market cap of $37.89M and a P/E ratio of -5.44. MREO moved +20.25% today. Year to date, MREO is -41.18%; over the trailing twelve months it is -87.71%. Its 52-week range spans $0.20 to $4.72. Analyst consensus is buy with an average price target of $2.33. Rallies surfaces MREO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns MREO stock?

Hedge funds tracked by Rallies that own MREO include Mangrove Partners. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Mereo BioPharma Group plc American Depositary Shares.

MREO Key Metrics

Key financial metrics for MREO
Metric	Value
Price	$0.28
Market Cap	$37.89M
P/E Ratio	-5.44
EPS	$-0.05
Dividend Yield	0.00%
52-Week High	$4.72
52-Week Low	$0.20
Volume	13.24K
Avg Volume	0
Revenue (TTM)	$500.00K
Net Income	$-41.88M
Gross Margin	0.00%

Top Hedge Funds Holding MREO

Mangrove Partners holds 7.79M shares of MREO, changed -9.79% as of Sep 30, 2025.

Latest MREO News

Mereo BioPharma Narrows Q1 Loss to $6.7M, Starts Pediatric Setrusumab Review — May 12, 2026
Mereo BioPharma Secures $41M Runway to Mid-2027 as Phase 3 Data Unfold — Mar 19, 2026
Mereo BioPharma Class Action Filed Over Failed Phase 3 Trials After 87% Share Collapse — Feb 14, 2026

Recent MREO Insider Trades

Scots-Knight Denise sold 60.05K (~$253.45K) on Sep 13, 2024.
Lewicki John A. sold 10.94K (~$46.17K) on Sep 13, 2024.
Sermon Charles sold 20.95K (~$88.41K) on Sep 13, 2024.

MREO Analyst Consensus

5 analysts cover MREO: 0 strong buy, 3 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $2.33.

Common questions about MREO

Who owns MREO stock?: Hedge funds tracked by Rallies that own MREO include Mangrove Partners. The latest tracked quarter is Sep 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Mereo BioPharma Group plc American Depositary Shares.
Does Rallies show 13F holders for MREO?: Yes. Rallies tracks hedge fund and 13F ownership data for MREO, including fund names, share counts, latest tracked quarter, and position changes when available.
Is MREO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MREO. It does not provide personalized investment advice.